{"id":"amt-676","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL5818723","moleculeType":null,"molecularWeight":"464.54"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By allosterically modulating the calcium-sensing receptor, AMT-676 increases the receptor's responsiveness to circulating calcium levels, thereby promoting parathyroid hormone (PTH) suppression and reducing serum calcium. This mechanism is intended to treat secondary hyperparathyroidism in patients with chronic kidney disease by restoring more physiologic calcium homeostasis without requiring exogenous calcium supplementation.","oneSentence":"AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:03.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT06400485","phase":"EARLY_PHASE1","title":"AMT-676 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2024-06-18","conditions":"Advanced Solid Tumors","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMT-676","genericName":"AMT-676","companyName":"Multitude Therapeutics Inc.","companyId":"multitude-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium. Used for Secondary hyperparathyroidism in patients with chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}